论文部分内容阅读
目的 研究苦参中对抗柯萨奇B3病毒 (CVB3)的有效成份 ,即抗柯萨奇注射液 (SFA)抗CVB3病毒的作用。方法 将心肌细胞分为 4组 ,感染组 (n =8) :只感染病毒 ,不加SFA ;治疗组 (n =8) :感染病毒后加入SFA(10 0mg/L) ;药物组 (n =6 ) :不感染病毒 ,只加入SFA(10 0mg/L) ;对照组 (n =6 ) ;不感染病毒 ,不加SFA。结果 在感染病毒后第 2、3、5d ,感染组心肌细胞的病变程度较其余 3组重 ,乳酸脱氢酶 (LDH)与谷草转氨酶 (SGOT)的浓度明显增高 ,与其余 3组比较差异有显著性 (P <0 .0 5 ) ,心肌细胞中病毒滴度比治疗组高 2 5 .12～ 15 8.5 0倍。SFA在 30 0mg/L浓度下对正常心肌细胞的结构和功能无影响 ;在 6 .2 5～ 2 0 0mg/L范围内对感染病毒的心肌细胞具有保护作用。结论 SFA可以抑制CVB3在心肌细胞中的复制。
Objective To study the effect of anti-CVB3 virus against Coxsackie B3 virus (CVB3), which is the anti-CVB3 virus in Coxsackie injection (SFA). Methods Cardiomyocytes were divided into 4 groups: infected group (n = 8): infected with virus only, no SFA added; treated group (n = 8): SFA (100 mg/L) was added after infection; drug group (n = 6) : No virus, only SFA (100 mg/L); control (n = 6); no virus, no SFA. Results On the 2nd, 3rd, and 5th days after infection, the lesions of myocardial cells in the infected group were heavier than those in the other 3 groups, and the concentrations of lactate dehydrogenase (LDH) and aspartate aminotransferase (SGOT) were significantly higher, compared with the other three groups. Significantly (P < 0.05), the virus titer in cardiomyocytes was 25-12.558 times higher than that of the treatment group. SFA had no effect on the structure and function of normal cardiomyocytes at a concentration of 30 mg/L, and had a protective effect on virus-infected cardiomyocytes in the range of 6.2-200 mg/L. Conclusion SFA can inhibit the replication of CVB3 in cardiomyocytes.